Select a Region North America


Brigham Hyde, PhD

President, Data and Analytics


Artificial Intelligence (AI), Data & Analytics, Data and Software, Digital Health, Digital Medicine, Digital Technology, Emerging Technology

Brigham is a highly regarded speaker and thought leader on the value of data and analytics across the life sciences, pharma, and overall healthcare sector. His background is in data science and artificial intelligence (AI) and he excels at building best-in-class data software technologies to empower executives to make informed choices.

Prior to joining EVERSANA, Brigham was the co-founder and President of Concerto Health AI and Healthcare Partner at Symphony AI. Concerto developed the definitive data set for real-world data and was a leader in AI solutions for precision oncology. He also served as the Chief Data Officer at Decision Resource Group, and was responsible for building the company’s overall data and analytics platform. Brigham is a member of Forbes Technology Council, an exclusive group of senior-level technology executives who discuss how emerging technologies can change the way we live. He is an adjunct professor of pharmacology and experimental therapeutics at Tufts University and Research Faculty at MIT Media Lab.

Brigham holds a PhD in Pharmacology and Experimental Therapeutics from Tufts University School of Medicine, and a bachelor’s degree in chemistry from Northeastern University.

Articles by Brigham Hyde, PhD

Measuring the Impact of Coordinated Field and Digital Engagement Through Network Influence: An Omnichannel Case Study

In today’s competitive global market, pharmaceutical companies can’t afford to waste time or resources on strategies that don’t generate scripts or fit product and patient needs. Without data-informed, fully integrated campaigns, there’s a missed opportunity to mine deep insights that can inform next steps and accurately pinpoint efforts to doctors and patients who could benefit […]

Turning Theory Into Action: How Real-World Evidence Drives Clinical Research and Improves Patient Outcomes

Life sciences companies have made significant investments in real-world data (RWD), but most established providers can deliver only a fraction of what’s needed to be impactful. Breaking down traditional healthcare silos for a more innovative approach to drug development can shorten the research and development timeline while substantially reducing wasted investments along the way. From […]

PharmaVOICE Digital Influencers: Brigham Hyde

Data Is Transforming the Landscape In a special feature on Digital Influencers, PharmaVOICE Editor Taren Grom sat down with Brigham Hyde, President, Data & Analytics to discuss how data is transforming the life sciences landscape as we know it. From the rise of personalized medicine and value-based healthcare to evolving commercial strategies, the effective utilization […]

How Artificial Intelligence Is Transforming Pharma

From drug discovery to clinical trials to commercialization, artificial intelligence (AI) and machine learning (ML) technologies are transforming the pharma and life sciences industries. Industry leaders who recognize the potential of AI and ML are now using these technologies to provide actionable market insights and enhanced data automation through platforms like ACTICS by EVERSANATM, created […]

Five Biggest Data Challenges for Life Sciences

Data is transforming the competitive landscape in life sciences. From the rise of personalized medicine and value-based healthcare to evolving commercial strategies, the effective utilization of data is critical to solving for better patient outcomes. There are significant challenges, however, including siloed, messy data quality; slow legacy systems delivering fragmented insights; and the inability to […]

Methodology for Predicting Switching Behaviors in Patients

Patient and hub services represent a significant and often ineffective spend surrounding overall patient support. How can we use data and analytics to build better patient services programs that predict next best actions and achieve improved patient engagement and outcomes across the treatment journey? As the industry continues its shift to value-based care, this challenge […]

Sharpening The Value And Definitions Of Digital And RWD: An Exchange Between Two Industry Leaders

The following is a exchange between Brigham Hyde and Ed Cox, two health tech experts and coworkers on a quest to educate each other and their teams. Note: An inquiry from a colleague who interchanged terminology initiated this exchange. Download the PDF Version  

A Predictive Analytics and Machine Learning Approach to Improving Hub Performance and Patient Outcomes

Today we have access to more data, from more sources than we could ever dream possible. Living in a digital world, we increasingly need the ability to efficiently and effectively process this data for insights and actions in order to be competitive. The life sciences industry can leverage this data using analytic tools and machine learning to rapidly identify patient behaviors and patterns – allowing us to predict “next best actions” in our quest to improve patient outcomes.

PharmaVOICE Connected Health Showcase

IF I COULD ONLY ASK TWO QUESTIONS, THE FIRST WOULD BE: What is your data integration and analytics platform strategy? As the industry continues its shift to a patient-centric, value-based model of care, it is critical that the next generation of patient services programs integrate data and analytics into their care models to track the […]

What is Your Data Integration and Analytics Platform Strategy?

If I Could Only Ask Two Questions, the First One Would Be: What is Your Data Integration and Analytics Platform Strategy? It’s really simple, data analytics drives decisions. In the healthcare industry, we use data to better understand the complexity of disease, improve forecasting and communications with patients, design more effective clinical trials, predict trends, […]

Interested in scheduling a meeting or speaking event?

Contact Us

  • This field is for validation purposes and should be left unchanged.